Premium
Serological Screening, Using Three Different Test Systems of Platelet‐Transfused Patients with Hematologic‐Oncologic Disorders
Author(s) -
Wernet Dorothee,
Schnaidt Martina,
Mayer Gerhard,
Northoff Hinnak
Publication year - 1993
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1111/j.1423-0410.1993.tb02125.x
Subject(s) - medicine , platelet , immunology , autoantibody , serology , isoantibodies , antibody , antigen , monoclonal antibody , lymphocyte , hematologic disorders , human leukocyte antigen , in vivo , immunofluorescence , biology , microbiology and biotechnology
Sera of hematologic‐oncologic patients were tested regularly after platelet transfusions in three test systems: lymphoeytotoxicity test, platelet adhesion immunofluorescence test, and — only selected sera — in the monoclonal antibody‐specific immobilization of platelet antigen test. Of 388 patients 53 (14%) had HLA antibodies 5 of these in combination with platelet‐specific alloantibodies. Lymphocyte‐restricted (non‐HLA) reactions were observed in 20 patients, the majority of which was attributed to lymphocyte‐specific auto‐ or alloantibodies. Sera of 27 patients showed platelet‐specific reactions, usually cold‐reacting autoantibodies which have no effect in vivo.